What species are included in an oral anaerobic biofilm model?

Our standard panel includes obligate anaerobes such as Fusobacterium nucleatum, Porphyromonas gingivalis, Prevotella intermedia, and Veillonella parvula, as well as facultative anaerobes like Streptococcus mutans when relevant. Custom consortia based on your target disease or clinical isolates can be assembled during scoping.

How do you ensure strict anaerobic conditions during handling?

All biofilm cultivation, drug addition, and sample processing are performed inside a dedicated anaerobic chamber with continuous gas monitoring (e.g., N₂/CO₂/H₂ mix). Media are pre-reduced, and all liquid transfers use oxygen-free techniques. Resazurin indicator is used to confirm anaerobiosis.

Can you evaluate both prevention and eradication of biofilms?

Yes. In the prevention model, the test compound is added at the time of inoculation. For eradication, compound exposure occurs after a mature biofilm (e.g., 48–72 h) has formed. Both protocols are available and can be run in parallel to discriminate anti-biofilm from antimicrobial activity.

How do you compare biofilm susceptibility to planktonic MIC?

We run a companion planktonic MIC assay (broth microdilution per CLSI M11 for anaerobes) using the same strains and drug concentrations. The ratio of biofilm EC50 to planktonic MIC (tolerance factor) is calculated to quantify the protection afforded by the biofilm mode of growth.

Is the service customizable for non-oral anaerobic pathogens?

While our expertise centers on oral anaerobes, the same anaerobic biofilm platforms can be adapted for other Gram-negative or Gram-positive anaerobes involved in wound, GI, or device-related infections. Please discuss your specific needs during project scoping.

What data do I need to provide to start a study?

We require the test compound(s) (typically 10–100 µL of stock solution), a preferred concentration range, and any existing MIC data or safety information. Selection of reference strains or clinical isolates can be guided by our scientists based on your target indication.

Services

Online Inquiry

Name *

Email *

Subject *

Phone

Your Message

How Did You Hear About Us

Oral Anaerobic Biofilm Drug Susceptibility Evaluation

Oral Microbiology Services

Standardized susceptibility testing against oral anaerobic biofilms to help drug developers select lead antimicrobial formulations for periodontitis therapy.

Anaerobic multi-species biofilm models relevant to periodontitis
Static and dynamic assay formats for prevention or eradication
Quantitative viability, biomass, and metabolic activity endpoints
Customizable strain panels including clinical isolates

Request Project Consultation

Why a dedicated anaerobic biofilm assay?

Biofilm-grown oral anaerobes can be up to 1,000-fold less susceptible to antibiotics than planktonic cultures. Standard MIC testing alone underestimates in vivo efficacy, making biofilm-specific evaluation essential for drug development.

Clinically relevant polymicrobial consortia
Strict anaerobic atmosphere throughout biofilm formation and treatment
Endpoints matched to your drug mechanism (cidal, static, anti-biofilm)
Direct comparison to planktonic controls

Reproducible

Policy-compliant

Actionable

Approach

Biofilm susceptibility testing designed for anaerobic oral pathogens

Our methodology models the structured, matrix-enclosed communities that characterize periodontitis-associated biofilms, enabling accurate assessment of antimicrobial penetration and killing.

Anaerobic biofilm formation & drug exposure

Multi-species biofilms (facultative and obligate anaerobes) are cultivated in controlled anaerobic conditions using microtiter, Calgary device, or coupon-based formats. Test compounds are applied under static or flow-through regimens to mimic clinical dosing.

Reference strains and clinical isolates from periodontitis patients
96‑, 24‑, or 6‑well plate formats for throughput
Single or repeated dose schemes, with optional nutrient replenishment

Quantitative efficacy endpoints

After exposure, biofilm viability is measured by colony-forming unit (CFU) enumeration, metabolic dye reduction, and biomass staining. Combined endpoints distinguish bactericidal from anti-biofilm effects.

CFU counts after biofilm dispersal
Resazurin / MTT metabolic activity
Crystal violet or safranin biomass quantification

Quality controls

Each assay includes growth controls, sterility checks, and a reference antibiotic (e.g., metronidazole or chlorhexidine) to validate system performance.

Statistical rigor

Minimum triplicate wells per condition; data are reported as mean ± SD with appropriate parametric or non-parametric testing and multiplicity correction.

Biological interpretation

Results are contextualized against planktonic MIC data, literature tolerance thresholds, and your compound's known mechanism to separate inhibition from eradication.

Deliverables

What you receive from each study

A comprehensive dataset and interpretative report that translates biofilm susceptibility into actionable decision criteria.

Data deliverables

Raw and processed viability (CFU/mL, metabolic units, OD/biomass)
Log-reduction tables for each test compound vs. control
Dose–response curves and IC₅₀ / EC₅₀ values where applicable
Comparison to planktonic MIC of the same strains

Reporting & support

Detailed study protocol with materials and methods
Graphical summary of results with statistical annotations
Scientific interpretation addressing tolerance vs. resistance
Consultation on next-step in vivo study design

Service Scope

Study parameters defined per project

Every evaluation is scoped to your compound class, target biofilm species, and regulatory stage. The table below lists typical customizable parameters.

Parameter	Typical project scope
Biofilm species	Oral anaerobes: Fusobacterium nucleatum, Porphyromonas gingivalis, Prevotella intermedia, Parvimonas micra, Veillonella parvula; facultative anaerobes as needed
Growth model	Static microtiter (96/24/6‑well), Calgary MBEC device, coupon-based (saliva-coated), or custom flow-cell
Biofilm maturation time	24–72 h anaerobic incubation; extended regimens for aged biofilm tolerance
Test compounds	Up to 10 test articles per study (concentration range and exposure schedule scoped with client)
Endpoints measured	CFU enumeration after biofilm dispersal, metabolic activity via resazurin or MTT reduction, and biomass quantification using crystal violet staining – selectable per project.
Controls	Growth control (no drug), vehicle control, positive control antibiotic (e.g., chlorhexidine 0.2% or metronidazole 4 µg/mL)
Replication	Technical triplicate minimum; biological replicates on request
Data format	Excel summary with raw data, graphical plots, and statistical analysis

Workflow

From project scoping to validated report

A structured five-step process ensures each study is tailored, executed under stringent anaerobic conditions, and interpreted for your development pipeline.

Project scoping & strain selection

We review your compound portfolio, target indication, and desired regulatory level. Together we select the biofilm species (reference strains, clinical isolates, or a predefined consortium) and define the assay format and endpoints.

Biofilm cultivation under anaerobic atmosphere

Biofilms are grown in a controlled anaerobic chamber (e.g., N₂/CO₂/H₂ atmosphere) on pre-conditioned surfaces appropriate to the model. Maturation time is set to achieve reproducible, thick, matrix-encased communities.

Compound exposure & treatment regimen

Test compounds are applied at scoped concentrations and exposure times (single dose, multiple doses, or continuous flow). Positive and negative controls are included in each run to validate system performance.

Biofilm disruption & viability quantification

After treatment, biofilms are washed, mechanically or enzymatically dispersed, and serially diluted for CFU enumeration. Parallel wells are processed for metabolic activity or biomass staining to provide orthogonal readouts.

Data analysis & interpretative report

Log reductions, dose–response curves, and statistical comparisons are calculated. A final report contextualizes results against planktonic susceptibility, literature tolerance thresholds, and your development stage, with recommendations for follow-up studies.

Applications

When to use oral anaerobic biofilm susceptibility testing

This service supports drug discovery and development across multiple stages, from hit identification to preclinical candidate selection.

Rank compound series by anti-biofilm potency

Compare analogues under identical biofilm conditions to select the most efficacious anti-infective candidate for periodontitis therapy.

Structure–activity relationship (SAR) against anaerobic biofilms
Identify compounds that overcome biofilm tolerance

Assess the potential for induced resistance

Repeated sub-MIC exposure experiments can reveal whether bacteria in biofilms develop reduced susceptibility over time.

Multi-passage resistance induction studies
Comparison of MIC drift between planktonic and biofilm states

Evaluate nano-carriers or sustained-release platforms

Biofilm models can test formulations designed to penetrate the matrix and maintain drug concentration locally, such as nano-doxycycline or hydrogel-based systems.

Dose–response with formulation versus free drug
Time-kill kinetics under simulated release conditions

FAQ

Common questions about anaerobic biofilm susceptibility evaluation

We address the technical and practical considerations that clients often raise before initiating a study.

Our standard panel includes obligate anaerobes such as Fusobacterium nucleatum, Porphyromonas gingivalis, Prevotella intermedia, and Veillonella parvula, as well as facultative anaerobes like Streptococcus mutans when relevant. Custom consortia based on your target disease or clinical isolates can be assembled during scoping.
All biofilm cultivation, drug addition, and sample processing are performed inside a dedicated anaerobic chamber with continuous gas monitoring (e.g., N₂/CO₂/H₂ mix). Media are pre-reduced, and all liquid transfers use oxygen-free techniques. Resazurin indicator is used to confirm anaerobiosis.
Yes. In the prevention model, the test compound is added at the time of inoculation. For eradication, compound exposure occurs after a mature biofilm (e.g., 48–72 h) has formed. Both protocols are available and can be run in parallel to discriminate anti-biofilm from antimicrobial activity.
We run a companion planktonic MIC assay (broth microdilution per CLSI M11 for anaerobes) using the same strains and drug concentrations. The ratio of biofilm EC50 to planktonic MIC (tolerance factor) is calculated to quantify the protection afforded by the biofilm mode of growth.
While our expertise centers on oral anaerobes, the same anaerobic biofilm platforms can be adapted for other Gram-negative or Gram-positive anaerobes involved in wound, GI, or device-related infections. Please discuss your specific needs during project scoping.
We require the test compound(s) (typically 10–100 µL of stock solution), a preferred concentration range, and any existing MIC data or safety information. Selection of reference strains or clinical isolates can be guided by our scientists based on your target indication.

Scientific Literature

References

Wuersching SN, Huth KC, Hickel R, et al. Targeting antibiotic tolerance in anaerobic biofilms associated with oral diseases: Human antimicrobial peptides LL-37 and lactoferricin enhance the antibiotic efficacy of amoxicillin, clindamycin and metronidazole. Anaerobe. 2021;71:102439. View on PubMed
Tidbury F, Brülhart G, Müller G, et al. Effectiveness and tolerability of lactic acid vaginal gel compared to oral metronidazole in the treatment of acute symptomatic bacterial vaginosis: a multicenter, randomized-controlled, head-to-head pilot study. BMC women's health. 2025;25(1):7. View on PubMed
Wolf M, Metz J, Wittmer A, et al. Using Selective Agar Containing Ciprofloxacin and Tetracycline Reveals Resistant Oral Microbiota in Healthy and Periodontitis Patients. MicrobiologyOpen. 2026;15(2):e70298. View on PubMed
Ma L, Du X, Pang C, et al. Reprogramming of pathogenic strategies in Fusobacterium nucleatum: a study based on an in vitro infection model. Frontiers in cellular and infection microbiology. 2026;16:1719385. View on PubMed

Please kindly note that our products and services are for research use only.